Table 2.

Patient and tumor characteristics of the locally advanced cohort, sorted by the AR pathway activity score

Patient no.	Gender	Tumor tissue	Tumor %	Age tissue (mo.)	AR	AR‐V7	AR IHC	AR pathway activity	AKR1C3	SRD5A1	SRD5A2	HER2 status	ADT	DFS (mo.)	OS (mo.)
31	M	T	70	18	1.187	0.042	6.0	37.9	0.121	0.883	0.003	Neg	Bica	18+	18+
32	F	T	60	6	4.045	0.812	6.0	42.9	0.351	3.364	0.005	Neg	LHRH + bica	5+	5+
33	M	T	40	108	1.014	0.045	6.0	44.4	0.007	0.164	0.002	Neg	Bica	17	52
34	M	T	70	12	0.886	0.006	6.0	45.3	0.883	1.050	0.028	Pos	Bica	10+	10+
35	F	T	80	3	4.441	0.237	5.5	46.0	0.829	7.062	0.046	–	LHRH + bica	2+	2+
36	M	T	70	3	4.056	0.162	4.5	48.4	0.829	1.117	0.003	–	Bica	3+	3+
37	M	T	30	13	5.046	0.081	6.0	48.8	0.732	5.429	0.007	Neg	Bica	6	8+
38	M	N	60	36	1.253	0.022	6.0	49.8	0.521	5.464	0.011	Neg	Bica	12	22
39	M	T	80	23	1.366	0.067	6.0	53.3	0.183	10.724	0.068	Neg	Bica	22	34+
40	M	T	40	10	2.235	0.084	6.0	54.0	1.357	6.635	0.002	Neg	Bica	11+	11+
41	M	T	70	18	1.886	0.116	6.0	54.4	0.369	1.905	0.012	Pos	Bica	15+	15+
42	M	T	50	30	1.663	0.048	6.0	58.6	0.532	22.098	0.052	–	Bica	25+	25+
43	M	T	70	9	6.755	0.147	6.0	59.6	0.737	46.340	0.004	Neg	Bica	11+	11+
44	M	T	70	14	0.657	0.020	4.5	61.6	0.198	7.835	0.222	Pos	Bica	15+	15+

Abbreviations: +, ongoing DFS/OS; ADT, androgen deprivation therapy; AKR1C3, aldo‐keto reductase family 1 member C3 gene expression; AR IHC, immunohistochemical androgen receptor expression; AR, androgen receptor gene expression; AR‐V7, androgen receptor splice variant 7 gene expression; bica, bicalutamide; DFS, disease‐free survival; F, female; M, male; mo., months; N, lymph node metastasis in neck; OS, overall survival; SRD5A, steroid 5 alpha‐reductase gene expression; T, primary tumor.